SETD2: H3K36 Methylation, Transcription and Repair

One Mark, Several Jobs

H3K36me3 is placed by SETD2 as RNA polymerase II moves through a gene. The mark is read by proteins that regulate co-transcriptional splicing, suppress spurious transcription from within gene bodies, and recruit the mismatch-repair machinery and factors that promote homologous recombination.

Because it touches transcription and repair, complete SETD2 loss has pleiotropic effects: altered splicing, a mild mutator phenotype and changes in replication timing.

Clear Cell Renal Cell Carcinoma

SETD2 sits on chromosome 3p alongside VHL, PBRM1 and BAP1. The 3p region is lost early in most clear cell renal cell carcinomas, and a second hit then inactivates the remaining SETD2 allele in a substantial minority of cases.

SETD2 loss in this setting has been associated with more aggressive disease features in some series, and mechanistic work links it to activation of Wnt/beta-catenin signalling among other pathways.

Interpretation

A SETD2 alteration is reported as a tumour finding; there is no established germline cancer syndrome and no approved targeted therapy. Its main value at present is as part of the molecular portrait of a renal or other tumour.

As with other large chromatin genes, distinguishing a driver truncating mutation from a passenger requires the clinical and genomic context.

Renal Cancer Context and Research Directions

In clear cell renal cell carcinoma, SETD2 is one of a group of chromosome-3p chromatin genes — with VHL, PBRM1 and BAP1 — whose combination shapes tumour behaviour. SETD2 loss alongside BAP1 loss has been linked to worse outcomes in some series, which is why these genes are reported together on renal tumour panels even without a targeted drug.

Research directions include exploiting the mild homologous-recombination and mismatch-repair defects that follow H3K36me3 loss, and targeting the altered metabolism and Wnt signalling described in SETD2-null models. None has translated into an approved therapy.

Key Takeaways

• ·SETD2 is the sole writer of H3K36me3, linking transcription elongation to splicing and DNA repair.
• ·It is co-located with VHL, PBRM1 and BAP1 on chromosome 3p and is lost in a subset of clear cell renal cancers.
• ·SETD2 status is currently descriptive, without a germline syndrome or approved targeted treatment.